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AbstrACt
Introduction Idiopathic nephrotic syndrome (INS) is 
characterised by a high relapse rate up to 80% after 
initial response to standard therapy with corticosteroids. 
Steroid toxicity is common and causes a great burden 
of disease that negatively influences the health-related 
quality of life (HRQoL). Recently, studies have shown that 
levamisole, an anthelminthic drug, significantly improves 
relapse-free survival in children with frequent relapses or 
steroid dependency. Compared with other steroid-sparing 
drugs, levamisole has relatively few side effects. We 
hypothesise that adding levamisole to standard therapy 
with corticosteroids in children with a first episode of 
INS will prevent relapses, decrease cumulative dosage of 
steroids used and improve HRQoL. This paper presents 
the study protocol for the LEARNS study (LEvamisole 
as Adjuvant therapy to Reduce relapses of Nephrotic 
Syndrome).
Methods and analysis An international, double-blind, 
placebo-controlled randomised trial will be conducted in 
20 participating hospitals in the Netherlands and Belgium. 
Participants (n=92) with a first episode of INS, aged 
2–16 years, who achieve remission after 4 weeks of oral 
prednisolone will be randomly assigned (1:1) to receive 
either levamisole 2.5 mg/kg alternate day or placebo 
added to prednisolone (18-week tapering schedule) for a 
total of 24 weeks. Follow-up will be until 2 years after first 
presentation. Additionally, parents and/or children will fill 
out five HRQoL questionnaires. Primary outcome of the 
LEARNS study is occurrence of relapses within 12 months 
after first presentation. Secondary outcomes include time 
to first relapse, cumulative steroid dose after 2 years, 
safety parameters and quality of life scores.
Ethics and dissemination The trial was approved by the 
Medical Ethical Committee. Results of the study will be 
published in a peer-reviewed journal.
trial registration number NL6826, 2017-001025-41
bACkground
Idiopathic nephrotic syndrome (INS) is a rare 
disease that predominantly affects young chil-
dren. In the Netherlands, the yearly incidence 
is 1.52 per 100 000 children (an estimated 
60 new cases per year).1 INS is character-
ised by proteinuria, hypoalbuminaemia and 
oedema. It is often accompanied by hyper-
lipidaemia. Initial treatment consists of 8–20 
weeks of corticosteroids, of which at least 4 
weeks single-daily dose of 60 mg/m2 followed 
by an alternate schedule.2 The vast majority 
of patients shows remission within 4 weeks, 
after which the diagnosis minimal change 
disease is assumed and no kidney biopsy 
is indicated.3 Unfortunately, 80% of the 
responders experience at least one relapse; 
half of those patients experiencing frequent 
relapses (FRNS) or becoming steroid-depen-
dent (SDNS).4 Relapses are further treated 
with steroids; however, steroids are associ-
ated with many side effects.5 In these cases, 
steroid-sparing drugs are recommended.2 
These include cyclophosphamide, calci-
neurin inhibitors, mycophenolate mofetil 
strengths and limitations of this study
 ► Investigator-initiated, multicentre, double-blind, ran-
domised, placebo-controlled study.
 ► Additional study on health-related quality of life.
 ► Homogenous patient population.
 ► Possibility to pool data with similar ongoing trial 
(Nephrovir-3).
 ► Sample size only powered on primary outcome (ie, 
not for subgroup analyses).
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(MMF) and rituximab. But still, all come with substantial 
toxicity. A promising steroid-sparing agent is levamisole, 
an anthelminthic drug mostly used in a veterinary setting. 
Levamisole is, contrary to other steroid-sparing drugs, 
not an immunosuppressant, but acts as an immunomod-
ulator. It has relatively few side effects of which neutro-
penia is the most serious and most common that requires 
frequent check-ups. Recent trials show a beneficial effect 
of adjuvant treatment with levamisole to corticosteroids 
in children with FRNS or SDNS, but also that treatment 
is safe.6–8 
In order to prevent the frequency of relapses, several 
steroid schedules for the treatment of the first episode of 
INS have been studied, for instance, comparing a longer 
with a shorter course.4 To our knowledge, no trials have 
been performed investigating the efficacy of levami-
sole as an adjuvant agent to initial steroid treatment on 
preventing relapses. Currently, a study similar to ours is 
underway in France (Nephrovir-3).
We hypothesise that adding levamisole to standard 
steroid treatment in children with a first episode of INS 
will prevent relapses. This is substantiated by the fact 
that (1) INS is characterised by a T helper cell (Th) 
type 2 (antibody-mediated) immune response, and that 
(2) levamisole is able to skew the Th type 2 response 
into a Th type 1 (cell-mediated) response,9 10 and thus, 
restoring the balance. The aim of the LEARNS study is 
to investigate the efficacy and safety of adjuvant levami-
sole in children with a first episode of INS by conducting 
a randomised, double-blind, placebo-controlled clinical 
trial in 20 hospitals in the Netherlands and Belgium. The 
trial is extended with a sub-study on the health-related 
quality of life (HRQoL).
MEthods And AnAlysIs
study design
The LEARNS study is an international, phase 3, double-
blind, parallel, two-arm, randomised, placebo-con-
trolled superiority trial. The study is coordinated by the 
Amsterdam University Medical Centers, University of 
Amsterdam and is conducted in 15 and 5 participating 
centres in the Netherlands and Belgium, respectively. 
Local investigators are paediatric nephrologists or paedi-
atricians with a special interest in paediatric nephrology 
in both university and local hospitals. Together, the 
participating sites cover a large geographical area. The 
expected total duration of the study is 4 years, consisting 
of 2 years of inclusion and 2 years of follow-up since first 
presentation (figure 1).
objectives
The primary objective of the study is to investigate 
the effect of additional levamisole to standard steroid 
therapy in comparison with placebo from 4 to 28 weeks 
(figure 1) after the start of the first episode of steroid-sen-
sitive INS (SSNS) in children (age 2–16 years) on the 
occurrence of any relapse within 12 months after first 
presentation.
Secondary objectives are:
 ► To investigate differences between the two study 
groups in time to first relapse, the number of relapses, 
cumulative steroid dosage and the occurrence of 
SDNS and FRNS in a 2-year period.
 ► To investigate HRQoL, psychosocial adjustment, 
parental distress at different stages of treatment 
(longitudinal and cross-sectional) and to identify 
medical and personal factors related to HRQoL.
 ► To investigate the consequences of the disease on days 
of missing school for children, (financial) problems 
for parents, outpatient visits and hospital admissions.
Population
Children between 2 and 16 years of age who present with 
a first episode of INS will be screened for eligibility. Those 
who achieve remission within 4 weeks of oral treatment 
with corticosteroids will be screened for inclusion in the 
randomised controlled trial (RCT). Remission is defined 
as the absence of proteinuria for three consecutive days, 
confirmed by quantitative urinalysis (protein–creatinine 
ratio <20 mg/mmol creatinine). All inclusion and exclu-
sion criteria are described in box 1. SSNS will be defined 
according to current guidelines.2
Intervention
After confirming the diagnosis of INS, all patients will 
be treated with oral prednisolone according to the 
French protocol, which is an 18-week tapering schedule 
(figure 1).11 In addition to prednisolone, all patients 
will receive vitamin D (400 IE/day for children <12 
years; 800 IE/day for children ≥12 years). When partic-
ipating in the trial, concomitant use of any immuno-
suppressive and/or stimulant medication other than 
prednisolone is prohibited. Because of their anti-pro-
teinuric actions, non-steroid anti-inflammatory drugs, 
ACE-inhibitors and angiotensin II-receptor blockers 
are prohibited as well. If remission is achieved at week 
4, study subjects will receive 2.5 mg/kg levamisole 
or placebo on alternate days for a total of 24 weeks 
(figure 1). The current dosage schedule has been estab-
lished in a previous study.12 The dose of the study medi-
cation is calculated based on the patient’s weight, with 
a maximum of 150 mg/dose. Prednisolone and study 
medication need to be taken simultaneously. A missed 
dose can be taken within 24 hours of scheduled time. 
After 24 hours or more, the dose will not be taken and 
the next dose will be as scheduled. Study treatment will 
be (temporarily) stopped in case of the following situ-
ations: relapse, neutropenia <500/mm3, elevated liver 
enzymes >5× upper limit of normal, at the patient’s 
and/or their parent’s request, and/or withdrawal of 
informed consent. More details of temporarily stop-
ping the study medication in case of moderate to mild 
neutropenia can be found in the online supplement 1. 
In case of a relapse, treatment will be determined by 
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the treating physician, but generally consists of daily 
prednisolone (60 mg/m2) until remission, followed by 
40 mg/m2 every other day for 6 weeks.
When using study medication, patients will have regular 
check-ups for monitoring disease activity and adverse 
events (table 1). Adverse events are defined by any unde-
sirable event that occurs after inclusion until 30 days after 
stopping study medication.
Investigational medicinal product
Levamisole (Elmisol) and placebo tablets are produced, 
according to Good Manufacturing Practices, and supplied 
by ACE Pharmaceuticals B.V., Zeewolde, The Netherlands. 
Elmisol is registered as an orphan drug (European Medi-
cines Agency, 2005). Currently, it is prescribed off-label 
for the treatment of SSNS in children. Tablets are avail-
able in four strengths: 5, 10, 25 and 50 mg. The placebo 
tablets will match the active drug tablets in appearance, 
taste and weight, and will only contain pharmacologically 
inactive substances. Bottles with tablets will be sent to the 
patient by the Academic Medical Center (AMC) clinical 
pharmacy.
Questionnaires
To investigate the effect of INS on the HRQoL, psycho-
social adaptation, school performance and parental 
distress, parents and patients (if 8 years and older) will be 
asked to complete HRQoL questionnaires at five different 
time points: at first presentation, at 4 weeks after presen-
tation (prednisolone only), at 28 weeks after presenta-
tion (after study treatment), at 1 year after presentation 
(primary endpoint) and at 2 years after presentation 
(end of study). Different validated HRQoL question-
naires will be used (table 2).13–15 The Paediatric Quality of 
Life Inventory Generic Scale 4.0 consists of both self and 
proxy reports including a broad age range (2–18 years).13 
Norm scores for a Dutch healthy norm population and 
for children with other chronic illnesses (eg, asthma) 
are available.16 17 The Strength and Difficulties Ques-
tionnaire (SDQ) assesses the psychosocial adjustment of 
children and adolescents.14 18 19 Lastly, the Distress Ther-
mometer for Parents is a brief screening instrument to 
identify distress and everyday problems in parents of chil-
dren with a chronic condition.15 20 In addition, general 
questionnaires regarding demographics, medication and 
Figure 1 Schematic overview of study design. AD, alternate days.
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compliance will be sent to all parents and/or children. 
KLIK (Dutch: Kwaliteit van Leven In Kaart) is a web-based 
platform for HRQoL questionnaires, developed by the 
Psychosocial Department of our hospital and used by over 
10 000 patients and 400 healthcare professionals.21 It is 
used for both daily clinical care and research in a broad 
paediatric field. In this study, the KLIK website ( www. hetk-
likt. nu) will be used for filling out the questionnaires; it 
will only be used for research purposes. In contrast to 
daily clinical use, the patient will not receive feedback 
by his or her treating physician. After registration on the 
website, parents and, if applicable, patients of 8 years and 
older receive a reminder by email 7 days prior to their 
next visit.
study endpoints
The primary endpoint of the study is the occurrence 
of a first relapse within 12 months (week 52) after first 
presentation. Relapse is defined as having proteinuria 
(3+ on urine dipstick confirmed by >200 mg/mmol creat-
inine on quantitative urinalysis) for three consecutive 
days.
Secondary endpoints can be found in box 2.
sample size
Sample size was calculated based on the superiority 
design of the trial, as well as on the intention-to-treat prin-
ciple and on the primary outcome of the study: occur-
rence of relapse within 12 months after first presentation. 
To achieve a power of 80% with a two-sided significance 
level of 5%, two groups of 41 subjects are needed to iden-
tify a reduction in relapse of 30% (from 75% relapse to 
45%), which is considered clinically relevant. A total of 82 
patients need to complete 2 years of follow-up. With an 
estimated drop-out rate of 10%, 92 patients in total need 
to be included for the RCT. It is expected that around 
90% of all children with a first episode of INS will be 
steroid sensitive.22 23 Additionally, we expect that about 
65% of the patients screened for eligibility are willing 
to participate.4 In conclusion, this means a total of 157 
patients need to be recruited. With an incidence of 60 new 
cases of INS per year in the Netherlands and 30 new cases 
per year in Belgium (estimated), an inclusion period of 2 
years is expected. After withdrawal of informed consent, 
no study subjects will be replaced.
box 1 Inclusion and exclusion criteria for participation in 
the randomised controlled trial
Inclusion criteria
First episode of steroid-sensitive INS, as defined by:
 ► Proteinuria (>200 mg/mmol creatinine).
 ► Hypoalbuminaemia (<25 g/L).
 ► Oedema.
Remission, defined by:
 ► Absence of proteinuria (<20 mg/mmol creatinine) for three consec-
utive days within 4 weeks of steroid treatment.
Complement C3 within normal range.
Age 2–16 years.
Written informed consent.
Weight >9 kg.
Ability to swallow 5 mg (placebo) tablet (successful swallowing test in 
children<6 years).
Negative pregnancy test in girls who are of childbearing potential.
Absence of contraindication for levamisole use, defined as neutropenia 
(<1500/mm3).
Exclusion criteria
Previous episode(s) of INS.
Steroid-resistant INS, defined by:
 ► Persistent proteinuria at 4 weeks after start steroid treatment.
Previous or current malignancy, diabetes mellitus, current liver disease 
or epileptic convulsions.
Hypersensitivity to levamisole or one of its substances (lactose).
Inability to comply with the study protocol.
Table 1 Overview of study visits. All assessments at week 0 are part of standard of care
Visit 0 R1 2 3 4 5 6 7 8 9
Relapse
EoS
Week 0 4 8 12 16 20 28 36 44 52 104
Informed consent X
Entry criteria X X
Medical history X X
Physical examination X X X X X X X X X X X X
Laboratory examination X X X X X X X X X X X (X)
(Serious) adverse events X X X X X X X
Prednisolone
Study medication
Quality of life X X X X X
Drug dispensing X X
Drug accountability X X
The colour shades indicate in which period prednisolone and study medication is used. 
EoS, end of study; R, randomisation; (X), if indicated by treating physician.
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recruitment
When patients present in one of the participating hospi-
tals (see online supplement 2) with a first episode of 
INS, they will be informed about the RCT, after which 
they receive further written information about the RCT. 
When a patient presents with a first episode of INS in a 
non-participating hospital, the coordinating study team 
is contacted. The treating paediatrician will explain the 
study briefly and, if patient and parents agree, they will 
receive further written information by email. If interested 
in participating in the trial, the patient will be referred 
to the nearest participating hospital. After 4 weeks, 
patients will be checked if remission has been achieved. 
If so, informed consent for the RCT will be obtained and 
when the patient meets all of the inclusion criteria and 
none of the exclusion criteria, he/she will be randomised 
(figure 2).
To make sure all paediatricians in non-participating 
centres are acquainted with the trial, a monthly reminder 
by email will be sent. Also, additional information about 
the study for paediatricians, general practitioners, 
parents and patients (as well as all patient information 
forms (PIFs)) will be available on the study website ( www. 
learns. nl). For questions, they can contact the coordi-
nating investigator.
randomisation
A total of 92 eligible patients will be randomly assigned 
to one of the two treatment arms in a 1:1 ratio, receiving 
either levamisole (treatment) or placebo (control) added 
to standard corticosteroid treatment. Block randomi-
sation will occur using block sizes of 2, 4 and 6, which 
will be randomly used in order to make concealment of 
allocation as accurate as possible while granting minimal 
differences in numbers between the two groups. Rando-
misation (week 4) will be performed by the local investi-
gator using CastorEDC. The local investigator is blinded 
for the outcome of randomisation; only members of the 
AMC clinical pharmacy have rights to view allocation of 
treatment. Patients, parents, medical and nursing staff, 
outcome assessors, monitors and data analysts are blinded 
to treatment allocation.
Treatment allocation will be blinded until the study 
has ended, all data has been collected, queries have been 
resolved and the database has been locked.
data collection and management
Patient data will be collected at every visit by the local inves-
tigator and/or coordinating investigator. Clinical data 
Table 2 Overview of quality of life questionnaires used per age range. At each time point, all questionnaires are provided
Age range
2–3 years 4 years 5–7 years 8–10 years 11–12 years 13–16 years
Parent about
parent
Parent about
parent
Parent about
parent
Parent about
parent
Parent about
parent
Parent about
parent
Sociodemographics* General General General General General General
Parental distress†   DT-P DT-P DT-P DT-P DT-P DT-P
Parent about
child
Parent about
child
Parent about
child
Parent about
child
Parent about
child
Parent about
child
QOL child PedsQL (2–4) PedsQL (2–4) PedsQL (5–7)
Psychosocial adjustment SDQ (2–3) SDQ (4–18) SDQ (4–18) SDQ (4–18) SDQ (4–18) SDQ (4–18)
Problems with medication and 
compliance
Medication and 
compliance
Medication and 
compliance
Medication and 
compliance
School School School
Child Child Child Child Child Child
QOL child PedsQL (8–12) PedsQL (8–12) PedsQL (13–18)
Psychosocial adjustment SDQ (11–16) SDQ (11–16)
Problem with medication and 
compliance
Medication and 
compliance
Medication and 
compliance
Medication and 
compliance
School School School School
*Once at baseline.
†By both parents, if applicable. 
 DT-P, Distress Thermometer for Parents; PedsQL, Paediatric   Quality of Life Inventory; QOL, quality of life; SDQ, Strengths and Difficulties Questionnaire. 
box 2 secondary endpoints are being compared between 
the intervention groups
 ► Time to first relapse (days).
 ► Relapse rate over 2-year period (n/year).
 ► Cumulative steroid dose over 2-year period (mg/m2).
 ► Number of (serious) adverse events (n).
 ► Number of treatment discontinuations (n).
 ► Proportion patients with FRNS or SDNS (%).
 ► Days of missing school (days), outpatient visits (n), hospitalisation 
days (days).
 ► HRQoL and psychosocial adaptation at different time points (see 
table 1):
 – Cross-sectional and longitudinal.
 – Comparison with healthy peers and other chronic diseases.
FRNS, frequent relapsing nephrotic syndrome; HRQoL, health-related quality of 
life; SDNS, steroid-dependent nephrotic syndrome.
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will be entered in the Good Clinical Practice compliant 
electronic data management system CastorEDC. Addi-
tionally, patients are asked to keep a diary on treatment 
compliance, adverse events, relapse (proteinuria) and 
days of illness and school absence. These data will also be 
collected on the electronic case report form. Question-
naires on HRQoL will be completed at home at sched-
uled time points on the KLIK website ( www. hetklikt. nu). 
After registering, parents receive a reminder to fill out 
questionnaires.
statistical analysis
The outcomes of all included study subjects will be 
analysed as intention-to-treat. For safety analysis, an ‘as 
treated’ population will be defined. Study subjects who are 
lost to follow-up, withdraw informed consent or stopped 
study medication prematurely will be analysed according 
to allocated treatment group (figure 2). All data that have 
been collected until withdrawal or lost to follow-up will 
be used for analyses. Missing values at baseline and/or 
follow-up will not be imputed. R Studio will be used for 
performing all statistical analyses. A p value of <0.05 will 
be considered statistically significant. Continuous data 
will be presented as means with SD or median with IQR, 
depending on distribution. For between group compar-
isons, a Student’s t-test in case of normal distribution 
or Mann-Whitney U test in case of non-normal distribu-
tion will be used. Categorical data will be presented as 
proportions and compared using a χ2 test. The primary 
outcome, the occurrence of a relapse at 1 year after first 
presentation, will be compared between groups using a 
χ2 test. Relapse-free survival will be presented as a Kaplan-
Meier survival curve. Multivariate analyses (age at onset, 
sex, ethnicity, time to remission and FRNS/SDNS) will be 
performed using Cox regression.
No interim analysis for either efficacy or futility will be 
performed. Safety reviews will be performed by the Data 
Safety Monitoring Board (DSMB) after 1 year or when 
25 patients have been included and have completed the 
24 weeks (week 28 after first presentation) using study 
medication.
Monitoring and safety
A risk analysis according to guidelines of the Dutch 
Federations of University Hospitals categorises the study 
as ‘moderate risk’. Although the risk of the study is 
Figure 2 CONSORT flowchart of study design. CONSORT, Consolidated Standards of Reporting Trials. 
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considered negligible, our paediatric study population 
may be considered vulnerable and, therefore, the risk was 
upgraded to moderate. The Clinical Research Unit of the 
AMC will monitor the study, both on site and remotely.
Additionally, a DSMB is established to oversee the inclu-
sion rate and to protect the safety of the study subjects 
and the integrity of the study data. The DSMB consists 
of four members: a paediatrician with experience as a 
member of the ethical committee (chair), a paediatric 
nephrologist, two methodologists and a nephrologist, 
all independent of the trial. The DSMB will meet every 
6 months, or sooner in case of a suspected unexpected 
serious adverse reaction (SUSAR). After 1 year or after 
25 subjects (whichever occurs first) have been included 
and completed 24 weeks of treatment with study medica-
tion, a safety assessment will be performed. No stopping 
rules have been defined. The coordinating study team 
is responsible for reporting serious adverse events and 
submitting annual safety reports to the central Medical 
Ethical Committee (MEC) and competent authority. 
SUSARs will be reported to the competent authority and 
MEC by ACE Pharmaceuticals in order to keep the study 
team blinded. The AMC clinical pharmacy will provide 
unblinding on request after approval by the principal 
investigator.
Patient and public involvement
The Dutch Kidney Patient Association (NVN) was involved 
in the design of the study. Together with the patients, the 
burden of the intervention was discussed, and, on special 
request from the NVN, a HRQoL study was implemented 
in the design. All published data will be made available to 
the patients through email and the study’s website.
EthICs And dIssEMInAtIon
Ethical approval
A notification of no objection has been obtained from 
the Dutch and Belgian competent authorities: Central 
Committee on Research Involving Human Subjects 
(CCMO) and Federal Association of Health and Medic-
inal Product, respectively. Substantial amendments will 
be submitted for review to the MECs and competent 
authorities. The study is registered at the EU Clinical 
Trials Register under number NL61906.018.17. The study 
will be conducted in line with the Declaration of Helsinki 
(2013) and the International Conference of Harmonisa-
tion-Good Clinical Practice guidelines.
Informed consent
Before any study-related (screening) procedures occur, 
written informed consent must have been obtained from 
patient’s parents or legal representatives and/or the 
patient, depending on the patient’s age. Children aged 
12 years and older need to sign informed consent in addi-
tion to their parents. Children <12 years of age will be 
informed about the study in a manner that matches their 
age and understanding. Patients and their parents will 
be informed about their right to withdraw consent at any 
time without having to provide reasons. In case of resis-
tance of the patient to any of the study procedures, the 
‘Code of conduct involving minor’ will be used as a guideline. 
PIFs and informed consent forms are all approved by the 
MEC.
Confidentiality
All patients have their own patient ID, generated by the 
hospital information system. Source data will be stored 
confidentially at the local sites under this patient’s hospital 
ID. Study data will be kept using a unique patient identi-
fication number. The investigators will keep this number 
strictly confidential. Only the investigators have access 
to the key. Handling personal data will comply with the 
latest General Data Protection Regulation Act (EU Direc-
tive, 25 May 2018). All data will be stored for 15 years after 
the end of the study.
dissemination policy
Prior to the start of the study, the LEARNS study was 
registered in the Dutch Trial Registry. Results will be 
published in (inter)national peer-reviewed scientific jour-
nals once the study is completed. Papers will be published 
according to the CCMO and International Committee for 
Medical Journal Editors guidelines. Final results will be 
made public to all participants.
dIsCussIon
The LEARNS study aims to demonstrate the efficacy and 
safety of adding levamisole to standard steroid therapy in 
children with a first episode of INS on reducing relapses 
by conducting a multicentre randomised, double-blind, 
placebo-controlled trial.
Previous research mainly focused on the duration 
and cumulative doses of prednisolone in children with 
a first episode of INS. Initially, longer duration of pred-
nisolone treatment was considered superior in order to 
prevent relapses. Recent, well-conducted studies have 
shown that treating patients with prednisolone longer (2 
or 3 vs 6 months) has no beneficial effects on relapse-
free survival.4 24–26 Still, in both groups, around 80% of 
the children experience one or more relapses. In 2006, a 
study by Hoyer et al on the efficacy of cyclosporine as adju-
vant to steroid therapy for a first episode of INS showed 
a significant decrease in relapses in the first 12 months. 
However, this effect disappeared after 18 months. 
Because of the high rate of adverse effects and the need 
for blood monitoring, the authors did not recommend 
the protocol as standard therapy for these patients.27 
Currently, the INTENT (Initial treatment of steroid-sensi-
tive idiopathic nephrotic syndrom in children with myco-
phenolate mofetil versus prednisone) study is ongoing. 
This open-label, randomised trial compares prednisone 
versus MMF as initial treatment in children with a first 
episode of SSNS.28 However, apart from these few studies, 
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no further improvement in the prevention of relapses 
after the first episode of INS has been made.
Relapses of INS consequently result in repeated courses 
of prednisolone and are often accompanied by steroid 
toxicity. Therefore, INS comes with a high burden of 
disease affecting HRQoL of both patients and their fami-
lies. Although it is known that HRQoL is impaired in 
children with kidney disease, these studies were mainly 
performed in children with end-stage renal disease.29 
Only few studies have been published on HRQoL in chil-
dren with INS.30–33 Not only do these children report a 
lower HRQoL compared with healthy peers, their parents 
report an even more pessimistic view.31 Additionally, 
it appears that the duration of the disease has a nega-
tive impact on HRQoL.32 However, these studies are of 
cross-sectional design and did not include disease status 
or medication. Preventing relapses may thus contribute 
to improving quality of life in INS patients and their 
families.
Levamisole is a promising steroid-sparing agent since 
it has relatively few side effects compared with other 
steroid-sparing drugs. This has been shown in several 
RCTs in children with FRNS and SDNS.6–8 12 34–37 Its mode 
of action is still poorly understood. It is believed that 
levamisole has immunomodulatory effects by shifting the 
Th2 immune response to a Th1 response,9 10 and/or has a 
direct effect on the podocyte by inducing glucocorticoid 
receptor signalling pathway and, in this way, mimics or 
enhances the effect of prednisolone.38
Furthermore, it must be stressed that in preventing the 
progression of INS to a chronic illness, research should 
focus on a permanent cure of the disease. We hypothe-
sise that adding levamisole to the standard treatment with 
corticosteroids in children with a first episode of INS will 
prevent future relapses and, thus, will contribute to a 
better quality of life by reducing the cumulative steroid 
dose.
Since a similar trial on the efficacy of levamisole is 
simultaneously conducted in the Paris area, we adapted 
the French protocol for initial steroid treatment of INS. 
The study treatment and primary outcome is similar in 
both studies, but the duration of follow-up is different: 12 
months compared with 24 months in our study. Addition-
ally, HRQoL questionnaires were originally not imple-
mented, but Nephrovir-3 has planned to participate in 
our HRQoL study.
The main strength of our study is its randomised, 
placebo-controlled design, conducted in 20 partici-
pating hospitals in the Netherlands and Belgium. In 
this way, an extensive, geographical area will be covered. 
Placebo-controlled RCTs remain the golden standard in 
comparing different treatment regimens. On the other 
hand, an important limitation of this study may be the 
size of the study population. We only powered for our 
primary outcome, not for subgroup analyses. In case of 
insufficient inclusions, we may pool our data with the 
Nephrovir-3 trial since we use similar treatment proto-
cols. Another limitation may be that the treatment of 
relapses is not standardised by our study protocol as we 
mainly focus on the initial treatment. However, in the 
Netherlands, relapses are almost always treated according 
to national guidelines.39
After completion, the LEARNS study may provide 
evidence for adjusting (inter)national protocols for the 
standard treatment of the first episode of INS. If adding 
levamisole would prevent relapses, the disease could 
be less prevalent and the burden of disease on both 
patient and society be lowered. This could also mean 
that repeated courses of corticosteroids will be no longer 
needed and toxicity will be minimal. Additionally, and 
not the least important, quality of life of the patients and 
their families could be improved.
trial status
The study started recruiting in April 2018 and is currently 
recruiting.
Author affiliations
1Paediatric Nephrology, Amsterdam UMC, University of Amsterdam, Amsterdam, The 
Netherlands
2Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The 
Netherlands
3Paediatric Nephrology, Radboudumc, Nijmegen, The Netherlands
4Psychosocial Department, Amsterdam UMC, University of Amsterdam, Amsterdam, 
The Netherlands
5Paediatric Nephrology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
6Hospital Pharmacy, Amsterdam UMC, University of Amsterdam, Amsterdam, The 
Netherlands
7Paediatric Nephrology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, 
The Netherlands
Contributors AHMB is the principal investigator of the LEARNS study, initiated 
the project and drafted the protocol together with LH, RAAM, SF, JAEvW and MFS. 
FV drafted this manuscript based on the METC approved protocol using the SPIRIT 
checklist. All authors critically reviewed and revised the manuscript and approved 
the final manuscript as submitted.
Funding The LEARNS study is fully funded by the Dutch Kidney Foundation 
by a Consortia Grant (project CP16.03). The consortium consists of Amsterdam 
UMC, location AMC (AHMB, LH, RAAM and SF) and location VUMC (JAEvW), and 
Radboudumc (MFS). 
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The LEARNS study (version 3.0) has been approved by the 
Medical Ethical Committee (MEC) of the Academic Medical Center, the Netherlands, 
and of the University Hospitals Leuven, Belgium. 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. El Bakkali L, Rodrigues Pereira R, Kuik DJ, et al. Nephrotic syndrome 
in The Netherlands: a population-based cohort study and a review of 
the literature. Pediatr Nephrol 2011;26:1241–6.
 2. Cattran DC, Feehally J, Cook HT. Kidney disease: Improving global 
outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical 
practice guideline for glomerulonephritis. Kidney Int 2012;2:139–274.
by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027011 on 1 August 2019. Downloaded from 
9Veltkamp F, et al. BMJ Open 2019;9:e027011. doi:10.1136/bmjopen-2018-027011
Open access
 3. International Study of Kidney Disease in Children. Nephrotic 
syndrome in children: prediction of histopathology from clinical 
and laboratory characteristics at time of diagnosis. Kidney Int 
1978;13:159–65.
 4. Teeninga N, Kist-van Holthe JE, van Rijswijk N, et al. Extending 
prednisolone treatment does not reduce relapses in childhood 
nephrotic syndrome. J Am Soc Nephrol 2013;24:149–59.
 5. McDonough AK, Curtis JR, Saag KG. The epidemiology of 
glucocorticoid-associated adverse events. Curr Opin Rheumatol 
2008;20:131–7.
 6. Gruppen MP, Bouts AH, Jansen-van der Weide MC, et al. A 
randomized clinical trial indicates that levamisole increases the time 
to relapse in children with steroid-sensitive idiopathic nephrotic 
syndrome. Kidney Int 2018;93:510–8.
 7. Abeyagunawardena AS, Karunadasa U, Jayaweera H, et al. 
Efficacy of higher-dose levamisole in maintaining remission in 
steroid-dependant nephrotic syndrome. Pediatric Nephrology 
2017;32:1363–7.
 8. Elmas AT, Tabel Y, Elmas ON. Short- and long-term efficacy of 
levamisole in children with steroid-sensitive nephrotic syndrome. Int 
Urol Nephrol 2013;45:1047–55.
 9. Szeto C, Gillespie KM, Mathieson PW. Levamisole induces 
interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 
2000;100:217–24.
 10. Fu Y, Wang T, Xiu L, et al. Levamisole promotes murine bone marrow 
derived dendritic cell activation and drives Th1 immune response in 
vitro and in vivo. Int Immunopharmacol 2016;31:57–65.
 11. É B, Broyer M, Dehennault M, et al. Syndrome néphrotique pur 
(ou néphrose) corticosensible de l’enfant: Protocole de traitement 
proposé par la Société de Néphrologie Pédiatrique. Nephrol Ther 
2005;1:150–6.
 12. Levamisole for corticosteroid-dependent nephrotic syndrome in 
childhood. The Lancet 1991;337:1555–7.
 13. Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric 
population health measure: feasibility, reliability, and validity. Ambul 
Pediatr 2003;3:329–41.
 14. Goodman R, Ford T, Simmons H, et al. Using the strengths 
and difficulties questionnaire (SDQ) to screen for child 
psychiatric disorders in a community sample. Int Rev Psychiatry 
2003;15:166–72.
 15. Haverman L, van Oers HA, Limperg PF, et al. Development and 
validation of the distress thermometer for parents of a chronically ill 
child. J Pediatr 2013;163:1140–6.
 16. Engelen V, Haentjens MM, Detmar SB, et al. Health related quality of 
life of Dutch children: psychometric properties of the PedsQL in the 
Netherlands. BMC Pediatr 2009;9:68.
 17. Schepers SA, van Oers HA, Maurice-Stam H, et al. Health related 
quality of life in Dutch infants, toddlers, and young children. Health 
Qual Life Outcomes 2017;15:1–8.
 18. van Widenfelt BM, Goedhart AW, Treffers PD, et al. Dutch version of 
the strengths and difficulties questionnaire (SDQ). Eur Child Adolesc 
Psychiatry 2003;12:281–9.
 19. Maurice-Stam H, Haverman L, Splinter A, et al. Dutch norms for 
the Strengths and Difficulties Questionnaire (SDQ) - parent form for 
children aged 2-18 years. Health Qual Life Outcomes 2018;16:123.
 20. van Oers HA, Schepers SA, Grootenhuis MA, et al. Dutch normative 
data and psychometric properties for the Distress Thermometer for 
Parents. Qual Life Res 2017;26:177–82.
 21. Haverman L, van Oers HA, Limperg PF, et al. Implementation of 
electronic patient reported outcomes in pediatric daily clinical 
practice: The KLIK experience. Clin Pract Pediatr Psychol 
2014;2:50–67.
 22. Tarshish P, Tobin JN, Bernstein J, et al. Prognostic significance of the 
early course of minimal change nephrotic syndrome: report of the 
International Study of Kidney Disease in Children. J Am Soc Nephrol 
1997;8:769–76.
 23. McKinney PA, Feltbower RG, Brocklebank JT, et al. Time trends and 
ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. 
Pediatr Nephrol 2001;16:1040–4.
 24. Sinha A, Saha A, Kumar M, et al. Extending initial prednisolone 
treatment in a randomized control trial from 3 to 6 months did not 
significantly influence the course of illness in children with steroid-
sensitive nephrotic syndrome. Kidney Int 2015;87:217–24.
 25. Yoshikawa N, Nakanishi K, Sako M, et al. A multicenter randomized 
trial indicates initial prednisolone treatment for childhood nephrotic 
syndrome for two months is not inferior to six-month treatment. 
Kidney Int 2015;87:225–32.
 26. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for 
nephrotic syndrome in children. Cochrane Database Syst Rev 
2015:CD001533.
 27. Hoyer PF, Brodeh J. Initial treatment of idiopathic nephrotic 
syndrome in children: prednisone versus prednisone plus 
cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 
2006;17:1151–7.
 28. Ehren R, Benz MR, Doetsch J, et al. Initial treatment of 
steroid-sensitive idiopathic nephrotic syndrome in children 
with mycophenolate mofetil versus prednisone: protocol for a 
randomised, controlled, multicentre trial (INTENT study). BMJ Open 
2018;8:e024882.
 29. Tjaden LA, Grootenhuis MA, Noordzij M, et al. Health-related quality 
of life in patients with pediatric onset of end-stage renal disease: 
state of the art and recommendations for clinical practice. Pediatr 
Nephrol 2016;31:1579–91.
 30. Mishra K, Ramachandran S, Firdaus S, et al. The impact of 
pediatric nephrotic syndrome on parents' health-related quality 
of life and family functioning: an assessment made by the 
PedsQL 4.0 family impact module. Saudi J Kidney Dis Transpl 
2015;26:285–92.
 31. Rüth EM, Landolt MA, Neuhaus TJ, et al. Health-related quality 
of life and psychosocial adjustment in steroid-sensitive nephrotic 
syndrome. J Pediatr 2004;145:778–83.
 32. Selewski DT, Troost JP, Massengill SF, et al. The impact of disease 
duration on quality of life in children with nephrotic syndrome: a 
Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 
2015;30:1467–76.
 33. Mitra S, Banerjee S. The impact of pediatric nephrotic syndrome on 
families. Pediatr Nephrol 2011;26:1235–40.
 34. Abeyagunawardena AS, Karunadasa U, Jayaweera H, et al. Efficacy 
of higher-dose levamisole in maintaining remission in steroid-
dependant nephrotic syndrome. Pediatr Nephrol 2017;32:1363–7.
 35. Kuźma-Mroczkowska E, Skrzypczyk P, Pańczyk-Tomaszewska M. 
Levamisole therapy in children with frequently relapsing and steroid-
dependent nephrotic syndrome: a single-center experience. Central 
European Journal of Immunology 2016;3:243–7.
 36. Bagga A, Sharma A, Srivastava RN. Levamisole therapy in 
corticosteroid-dependent nephrotic syndrome. Pediatr Nephrol 
1997;11:415–7.
 37. Al-Ibrahim AA, Al-Kharraz SM, Al-Sadoon DM, et al. Levamisole 
therapy as a second-line immunosuppressive agent in corticosteroid-
sensitive nephrotic syndrome in children. Saudi J Kidney Dis Transpl 
2003;14:153–7.
 38. Jiang L, Dasgupta I, Hurcombe JA, et al. Levamisole in steroid-
sensitive nephrotic syndrome: usefulness in adult patients and 
laboratory insights into mechanisms of action via direct action on the 
kidney podocyte. Clin Sci 2015;128:883–93.
 39. Lilien MR, Vande W. Nefrotisch syndroom. In: Werkboek 
Kindernefrologie, 2010:124–31.
by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027011 on 1 August 2019. Downloaded from 
